West Palm Beach, FL, September 22, 2011 --(PR.com
)-- Spartan Bioscience Inc. is a molecular diagnostics company that provides DNA testing systems for decentralized and point-of-care (POC) applications. The Spartan RX CYP2C19 is a sample-to-result POC system for CYP2C19 genotyping. It is easy to use and provides genetic results in 1 hour. The Spartan RX CYP2C19 has CE IVD Mark regulatory approval. It is not currently available for sale in the United States.
“Spartan Bioscience has developed the first DNA testing system that is fast and easy to use,” said Larry D’Andrea, CEO, Spartan Bioscience. “WMT & GHC attracts leading medical tourism hospitals and private hospital networks from around the world. We are excited to demonstrate our product at WMT & GHC because it provides important genetic results and represents a new high-margin revenue opportunity for our customers,” he added.
This is the one event per year where Employers, Self Funded Health Plans, Insurance Companies, and Medical Tourism Facilitators that are looking to outsource healthcare overseas have the opportunity to meet with top International Hospitals and Medical Tourism Companies in one place for the ultimate networking event. As a Silver Sponsor, Spartan Bioscience will receive multiple benefits including recognition throughout the conference and preferred exhibit booth placement.
This year the MTA has allocated a budget to bring in up to 400 buyers of healthcare that includes global multinational employers, insurance companies and health insurance agents. The conference will feature over 150 exhibitors and sponsors, 100+ speakers and up to 1,500 attendees from over 87 countries. Save the date today by going to the Medical Tourism Congress website and register for this once a year event.